Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Progress in Vaccine-Preventable and Respiratory Infectious Diseases-First 10 Years of the CDC National Center for Immunization and Respiratory Diseases, 2006-2015.

Schuchat A, Anderson LJ, Rodewald LE, Cox NJ, Hajjeh R, Pallansch MA, Messonnier NE, Jernigan DB, Wharton M.

Emerg Infect Dis. 2018 Jul;24(7):1178-1187. doi: 10.3201/eid2407.171699.

2.

Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Liang JL, Tiwari T, Moro P, Messonnier NE, Reingold A, Sawyer M, Clark TA.

MMWR Recomm Rep. 2018 Apr 27;67(2):1-44. doi: 10.15585/mmwr.rr6702a1.

3.

Correction: Identifying Optimal Vaccination Strategies for Serogroup A Neisseria meningitidis Conjugate Vaccine in the African Meningitis Belt.

Tartof S, Cohn A, Tarbangdo F, Djingarey MH, Messonnier N, Clark TA, Kambou JL, Novak R, Diomandé FVK, Medah I, Jackson ML.

PLoS One. 2017 Dec 19;12(12):e0190188. doi: 10.1371/journal.pone.0190188. eCollection 2017.

4.

Effectiveness and Duration of Protection of One Dose of a Meningococcal Conjugate Vaccine.

Cohn AC, MacNeil JR, Harrison LH, Lynfield R, Reingold A, Schaffner W, Zell ER, Plikaytis B, Wang X, Messonnier NE; Active Bacterial Core Surveillance (ABCs) Team and MeningNet Surveillance Partners.

Pediatrics. 2017 Feb;139(2). pii: e20162193. doi: 10.1542/peds.2016-2193.

5.

Immune Responses in U.S. Military Personnel Who Received Meningococcal Conjugate Vaccine (MenACWY) Concomitantly with Other Vaccines Were Higher than in Personnel Who Received MenACWY Alone.

Broderick MP, Romero-Steiner S, Rajam G, Johnson SE, Milton A, Kim E, Choi LJ, Radin JM, Schmidt DS, Carlone GM, Messonnier N, Faix DJ.

Clin Vaccine Immunol. 2016 Aug 5;23(8):672-80. doi: 10.1128/CVI.00267-16. Print 2016 Aug.

6.

Public Health Impact After the Introduction of PsA-TT: The First 4 Years.

Diomandé FV, Djingarey MH, Daugla DM, Novak RT, Kristiansen PA, Collard JM, Gamougam K, Kandolo D, Mbakuliyemo N, Mayer L, Stuart J, Clark T, Tevi-Benissan C, Perea WA, Preziosi MP, Marc LaForce F, Caugant D, Messonnier N, Walker O, Greenwood B.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S467-72. doi: 10.1093/cid/civ499.

7.

Population-Based Surveillance of Neisseria meningitidis Antimicrobial Resistance in the United States.

Harcourt BH, Anderson RD, Wu HM, Cohn AC, MacNeil JR, Taylor TH, Wang X, Clark TA, Messonnier NE, Mayer LW.

Open Forum Infect Dis. 2015 Aug 13;2(3):ofv117. doi: 10.1093/ofid/ofv117. eCollection 2015 Sep.

8.

Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic.

Acosta AM, DeBolt C, Tasslimi A, Lewis M, Stewart LK, Misegades LK, Messonnier NE, Clark TA, Martin SW, Patel M.

Pediatrics. 2015 Jun;135(6):981-9. doi: 10.1542/peds.2014-3358. Epub 2015 May 4.

9.

Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization.

Meyer SA, Kambou JL, Cohn A, Goodson JL, Flannery B, Medah I, Messonnier N, Novak R, Diomande F, Djingarey MH, Clark TA, Yameogo I, Fall A, Wannemuehler K.

Vaccine. 2015 Mar 17;33(12):1492-8. doi: 10.1016/j.vaccine.2015.01.043. Epub 2015 Jan 28.

10.

Changes in the Population Structure of Invasive Neisseria meningitidis in the United States After Quadrivalent Meningococcal Conjugate Vaccine Licensure.

Wang X, Shutt KA, Vuong JT, Cohn A, MacNeil J, Schmink S, Plikaytis B, Messonnier NE, Harrison LH, Clark TA, Mayer LW.

J Infect Dis. 2015 Jun 15;211(12):1887-94. doi: 10.1093/infdis/jiu842. Epub 2015 Jan 2.

PMID:
25556253
11.

Meningococcal carriage among Georgia and Maryland high school students.

Harrison LH, Shutt KA, Arnold KE, Stern EJ, Pondo T, Kiehlbauch JA, Myers RA, Hollick RA, Schmink S, Vello M, Stephens DS, Messonnier NE, Mayer LW, Clark TA.

J Infect Dis. 2015 Jun 1;211(11):1761-8. doi: 10.1093/infdis/jiu679. Epub 2014 Dec 11.

12.

Persistence of serogroup C antibody responses following quadrivalent meningococcal conjugate vaccination in United States military personnel.

Patel M, Romero-Steiner S, Broderick MP, Thomas CG, Plikaytis BD, Schmidt DS, Johnson SE, Milton AS, Carlone GM, Clark TA, Messonnier NE, Cohn AC, Faix DJ.

Vaccine. 2014 Jun 24;32(30):3805-9. doi: 10.1016/j.vaccine.2014.05.001. Epub 2014 May 14.

13.

Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP).

Briere EC, Rubin L, Moro PL, Cohn A, Clark T, Messonnier N; Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC.

MMWR Recomm Rep. 2014 Feb 28;63(RR-01):1-14.

14.

Neisseria meningitidis serogroup W, Burkina Faso, 2012.

MacNeil JR, Medah I, Koussoubé D, Novak RT, Cohn AC, Diomandé FV, Yelbeogo D, Kambou JL, Tarbangdo TF, Ouédraogo-Traoré R, Sangaré L, Hatcher C, Vuong J, Mayer LW, Djingarey MH, Clark TA, Messonnier NE.

Emerg Infect Dis. 2014 Mar;20(3):394-9. doi: 10.3201/eid2003.131407.

15.

Global practices of meningococcal vaccine use and impact on invasive disease.

Ali A, Jafri RZ, Messonnier N, Tevi-Benissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S, Zhujun S, Bhutta Z, Abramson J.

Pathog Glob Health. 2014 Jan;108(1):11-20. doi: 10.1179/2047773214Y.0000000126. Review.

16.

Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women.

Meaney-Delman D, Zotti ME, Creanga AA, Misegades LK, Wako E, Treadwell TA, Messonnier NE, Jamieson DJ; Workgroup on Anthrax in Pregnant and Postpartum Women.

Emerg Infect Dis. 2014 Feb;20(2). doi: 10.3201/eid2002.130611.

17.

Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults.

Hendricks KA, Wright ME, Shadomy SV, Bradley JS, Morrow MG, Pavia AT, Rubinstein E, Holty JE, Messonnier NE, Smith TL, Pesik N, Treadwell TA, Bower WA; Workgroup on Anthrax Clinical Guidelines.

Emerg Infect Dis. 2014 Feb;20(2). doi: 10.3201/eid2002.130687.

18.

Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial.

Wright JG, Plikaytis BD, Rose CE, Parker SD, Babcock J, Keitel W, El Sahly H, Poland GA, Jacobson RM, Keyserling HL, Semenova VA, Li H, Schiffer J, Dababneh H, Martin SK, Martin SW, Marano N, Messonnier NE, Quinn CP.

Vaccine. 2014 Feb 12;32(8):1019-28. doi: 10.1016/j.vaccine.2013.10.039. Epub 2013 Dec 25.

PMID:
24373307
19.

Geotemporal analysis of Neisseria meningitidis clones in the United States: 2000-2005.

Wiringa AE, Shutt KA, Marsh JW, Cohn AC, Messonnier NE, Zansky SM, Petit S, Farley MM, Gershman K, Lynfield R, Reingold A, Schaffner W, Thompson J, Brown ST, Lee BY, Harrison LH.

PLoS One. 2013 Dec 12;8(12):e82048. doi: 10.1371/journal.pone.0082048. eCollection 2013.

20.

Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States.

Pawloski LC, Queenan AM, Cassiday PK, Lynch AS, Harrison MJ, Shang W, Williams MM, Bowden KE, Burgos-Rivera B, Qin X, Messonnier N, Tondella ML.

Clin Vaccine Immunol. 2014 Feb;21(2):119-25. doi: 10.1128/CVI.00717-13. Epub 2013 Nov 20.

21.

Global epidemiology of invasive meningococcal disease.

Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S, Zhujun S, Bhutta ZA, Abramson J.

Popul Health Metr. 2013 Sep 10;11(1):17. doi: 10.1186/1478-7954-11-17.

22.

Identifying optimal vaccination strategies for serogroup A Neisseria meningitidis conjugate vaccine in the African meningitis belt.

Tartof S, Cohn A, Tarbangdo F, Djingarey MH, Messonnier N, Clark TA, Kambou JL, Novak R, Diomandé FV, Medah I, Jackson ML.

PLoS One. 2013 May 9;8(5):e63605. doi: 10.1371/journal.pone.0063605. Print 2013. Erratum in: PLoS One. 2017 Dec 19;12 (12 ):e0190188.

23.

Prolonged university outbreak of meningococcal disease associated with a serogroup B strain rarely seen in the United States.

Mandal S, Wu HM, MacNeil JR, Machesky K, Garcia J, Plikaytis BD, Quinn K, King L, Schmink SE, Wang X, Mayer LW, Clark TA, Gaskell JR, Messonnier NE, DiOrio M, Cohn AC.

Clin Infect Dis. 2013 Aug;57(3):344-8. doi: 10.1093/cid/cit243. Epub 2013 Apr 17.

PMID:
23595832
24.

Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE; Centers for Disease Control and Prevention (CDC).

MMWR Recomm Rep. 2013 Mar 22;62(RR-2):1-28.

25.

Waning immunity to pertussis following 5 doses of DTaP.

Tartof SY, Lewis M, Kenyon C, White K, Osborn A, Liko J, Zell E, Martin S, Messonnier NE, Clark TA, Skoff TH.

Pediatrics. 2013 Apr;131(4):e1047-52. doi: 10.1542/peds.2012-1928. Epub 2013 Mar 11.

PMID:
23478868
26.

Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt.

Dakar discussion group on priorities for research on epidemic meningococcal disease in Africa, Altmann D, Aseffa A, Bash M, Basta N, Borrow R, Broome C, Caugant D, Clark T, Collard JM, Djingarey M, Goldblatt D, Greenwood B, Griffiths U, Hajjeh R, Hassan-King M, Hugonnet S, Kimball AM, LaForce M, MacLennan C, Maiden MC, Manigart O, Mayer L, Messonnier N, Moisi J, Moore K, Moto DD, Mueller J, Nascimento M, Obaro S, Ouedraogo R, Page AL, Perea W, Pluschke G, Preziosi MP, Sow S, Stephens D, Stuart J, Thomson M, Tiendrebeogo S, Trape JF, Vernet G.

Vaccine. 2013 Mar 1;31(11):1453-7. doi: 10.1016/j.vaccine.2012.12.035. Epub 2012 Dec 27.

27.

Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010.

Misegades LK, Winter K, Harriman K, Talarico J, Messonnier NE, Clark TA, Martin SW.

JAMA. 2012 Nov 28;308(20):2126-32. doi: 10.1001/jama.2012.14939.

PMID:
23188029
28.

Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity.

Kristiansen PA, Diomandé F, Ba AK, Sanou I, Ouédraogo AS, Ouédraogo R, Sangaré L, Kandolo D, Aké F, Saga IM, Clark TA, Misegades L, Martin SW, Thomas JD, Tiendrebeogo SR, Hassan-King M, Djingarey MH, Messonnier NE, Préziosi MP, Laforce FM, Caugant DA.

Clin Infect Dis. 2013 Feb;56(3):354-63. doi: 10.1093/cid/cis892. Epub 2012 Oct 19.

PMID:
23087396
29.

Estimating the effectiveness of acellular pertussis vaccines.

Misegades LK, Martin SW, Messonnier NE, Clark TA.

Clin Infect Dis. 2012 Nov 15;55(10):1432-3; author reply 1435-6. doi: 10.1093/cid/cis669. Epub 2012 Aug 7. No abstract available.

PMID:
22871824
30.

Haemophilus influenzae type b disease and vaccine booster dose deferral, United States, 1998-2009.

Briere EC, Jackson M, Shah SG, Cohn AC, Anderson RD, MacNeil JR, Coronado FM, Mayer LW, Clark TA, Messonnier NE.

Pediatrics. 2012 Sep;130(3):414-20. doi: 10.1542/peds.2012-0266. Epub 2012 Aug 6.

31.

Zoonotic infections among employees from Great Smoky Mountains and Rocky Mountain National Parks, 2008-2009.

Adjemian J, Weber IB, McQuiston J, Griffith KS, Mead PS, Nicholson W, Roche A, Schriefer M, Fischer M, Kosoy O, Laven JJ, Stoddard RA, Hoffmaster AR, Smith T, Bui D, Wilkins PP, Jones JL, Gupton PN, Quinn CP, Messonnier N, Higgins C, Wong D.

Vector Borne Zoonotic Dis. 2012 Nov;12(11):922-31. doi: 10.1089/vbz.2011.0917. Epub 2012 Jul 26.

32.

Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.

Novak RT, Kambou JL, Diomandé FV, Tarbangdo TF, Ouédraogo-Traoré R, Sangaré L, Lingani C, Martin SW, Hatcher C, Mayer LW, Laforce FM, Avokey F, Djingarey MH, Messonnier NE, Tiendrébéogo SR, Clark TA.

Lancet Infect Dis. 2012 Oct;12(10):757-64. doi: 10.1016/S1473-3099(12)70168-8. Epub 2012 Jul 18.

33.

Haemophilus haemolyticus isolates causing clinical disease.

Anderson R, Wang X, Briere EC, Katz LS, Cohn AC, Clark TA, Messonnier NE, Mayer LW.

J Clin Microbiol. 2012 Jul;50(7):2462-5. doi: 10.1128/JCM.06575-11. Epub 2012 May 9.

34.

Whole genome sequencing to investigate the emergence of clonal complex 23 Neisseria meningitidis serogroup Y disease in the United States.

Krauland MG, Dunning Hotopp JC, Riley DR, Daugherty SC, Marsh JW, Messonnier NE, Mayer LW, Tettelin H, Harrison LH.

PLoS One. 2012;7(4):e35699. doi: 10.1371/journal.pone.0035699. Epub 2012 Apr 27.

35.

Does tetanus-diphtheria-acellular pertussis vaccination interfere with serodiagnosis of pertussis infection?

Pawloski LC, Kirkland KB, Baughman AL, Martin MD, Talbot EA, Messonnier NE, Tondella ML.

Clin Vaccine Immunol. 2012 Jun;19(6):875-80. doi: 10.1128/CVI.05686-11. Epub 2012 Apr 25.

36.

Pertussis control: time for something new?

Clark TA, Messonnier NE, Hadler SC.

Trends Microbiol. 2012 May;20(5):211-3. doi: 10.1016/j.tim.2012.03.003. Epub 2012 Apr 9.

PMID:
22494804
37.

Inching toward a serogroup B meningococcal vaccine for infants.

Cohn AC, Messonnier NE.

JAMA. 2012 Feb 8;307(6):614-5. doi: 10.1001/jama.2012.118. No abstract available.

PMID:
22318284
38.

Modeling insights into Haemophilus influenzae type b disease, transmission, and vaccine programs.

Jackson ML, Rose CE, Cohn A, Coronado F, Clark TA, Wenger JD, Bulkow L, Bruce MG, Messonnier NE, Hennessy TW.

Emerg Infect Dis. 2012 Jan;18(1):13-20. doi: 10.3201/eid1801.110336.

39.

Pertussis Pseudo-outbreak linked to specimens contaminated by Bordetella pertussis DNA From clinic surfaces.

Mandal S, Tatti KM, Woods-Stout D, Cassiday PK, Faulkner AE, Griffith MM, Jackson ML, Pawloski LC, Wagner B, Barnes M, Cohn AC, Gershman KA, Messonnier NE, Clark TA, Tondella ML, Martin SW.

Pediatrics. 2012 Feb;129(2):e424-30. doi: 10.1542/peds.2011-1710. Epub 2012 Jan 16.

PMID:
22250029
40.

Early Impact of the US Tdap vaccination program on pertussis trends.

Skoff TH, Cohn AC, Clark TA, Messonnier NE, Martin SW.

Arch Pediatr Adolesc Med. 2012 Apr;166(4):344-9. doi: 10.1001/archpediatrics.2011.1093. Epub 2012 Jan 2.

PMID:
22213608
41.

Clinical validation of multiplex real-time PCR assays for detection of bacterial meningitis pathogens.

Wang X, Theodore MJ, Mair R, Trujillo-Lopez E, du Plessis M, Wolter N, Baughman AL, Hatcher C, Vuong J, Lott L, von Gottberg A, Sacchi C, McDonald JM, Messonnier NE, Mayer LW.

J Clin Microbiol. 2012 Mar;50(3):702-8. doi: 10.1128/JCM.06087-11. Epub 2011 Dec 14.

42.

Comparative study of different sources of pertussis toxin (PT) as coating antigens in IgG anti-PT enzyme-linked immunosorbent assays.

Kapasi A, Meade BD, Plikaytis B, Pawloski L, Martin MD, Yoder S, Rock MT, Coddens S, Haezebroeck V, Fievet-Groyne F, Bixler G, Jones C, Hildreth S, Edwards KM, Messonnier NE, Tondella ML.

Clin Vaccine Immunol. 2012 Jan;19(1):64-72. doi: 10.1128/CVI.05460-11. Epub 2011 Nov 23.

43.

Adolescent vaccination-coverage levels in the United States: 2006-2009.

Stokley S, Cohn A, Dorell C, Hariri S, Yankey D, Messonnier N, Wortley PM.

Pediatrics. 2011 Dec;128(6):1078-86. doi: 10.1542/peds.2011-1048. Epub 2011 Nov 14.

PMID:
22084326
44.

Current epidemiology and trends in invasive Haemophilus influenzae disease--United States, 1989-2008.

MacNeil JR, Cohn AC, Farley M, Mair R, Baumbach J, Bennett N, Gershman K, Harrison LH, Lynfield R, Petit S, Reingold A, Schaffner W, Thomas A, Coronado F, Zell ER, Mayer LW, Clark TA, Messonnier NE.

Clin Infect Dis. 2011 Dec;53(12):1230-6. doi: 10.1093/cid/cir735.

PMID:
22080119
45.

Haemophilus influenzae type b carriage among young children in metropolitan Atlanta in the context of vaccine shortage and booster dose deferral.

Thomas JD, Jackson ML, Sharma D, Mair R, Bach MC, Castillo D, Ejigiri OG, Satola S, Cohn AC, Jerris R, Jain S, Farley MM, Mayer LW, Messonnier NE.

Clin Vaccine Immunol. 2011 Dec;18(12):2178-80. doi: 10.1128/CVI.05254-11. Epub 2011 Oct 19.

46.

Identifying host genetic risk factors in the context of public health surveillance for invasive pneumococcal disease.

Lingappa JR, Dumitrescu L, Zimmer SM, Lynfield R, McNicholl JM, Messonnier NE, Whitney CG, Crawford DC.

PLoS One. 2011;6(8):e23413. doi: 10.1371/journal.pone.0023413. Epub 2011 Aug 15.

47.

Bacterial meningitis in the United States, 1998-2007.

Thigpen MC, Whitney CG, Messonnier NE, Zell ER, Lynfield R, Hadler JL, Harrison LH, Farley MM, Reingold A, Bennett NM, Craig AS, Schaffner W, Thomas A, Lewis MM, Scallan E, Schuchat A; Emerging Infections Programs Network.

N Engl J Med. 2011 May 26;364(21):2016-25. doi: 10.1056/NEJMoa1005384.

48.

sodC-based real-time PCR for detection of Neisseria meningitidis.

Dolan Thomas J, Hatcher CP, Satterfield DA, Theodore MJ, Bach MC, Linscott KB, Zhao X, Wang X, Mair R, Schmink S, Arnold KE, Stephens DS, Harrison LH, Hollick RA, Andrade AL, Lamaro-Cardoso J, de Lemos AP, Gritzfeld J, Gordon S, Soysal A, Bakir M, Sharma D, Jain S, Satola SW, Messonnier NE, Mayer LW.

PLoS One. 2011 May 5;6(5):e19361. doi: 10.1371/journal.pone.0019361.

49.

Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States.

Wang X, Cohn A, Comanducci M, Andrew L, Zhao X, MacNeil JR, Schmink S, Muzzi A, Bambini S, Rappuoli R, Pizza M, Murphy E, Hoiseth SK, Jansen KU, Anderson AS, Harrison LH, Clark TA, Messonnier NE, Mayer LW.

Vaccine. 2011 Jun 24;29(29-30):4739-44. doi: 10.1016/j.vaccine.2011.04.092. Epub 2011 May 13.

PMID:
21571026
50.

Detection of bacterial pathogens in Mongolia meningitis surveillance with a new real-time PCR assay to detect Haemophilus influenzae.

Wang X, Mair R, Hatcher C, Theodore MJ, Edmond K, Wu HM, Harcourt BH, Carvalho Mda G, Pimenta F, Nymadawa P, Altantsetseg D, Kirsch M, Satola SW, Cohn A, Messonnier NE, Mayer LW.

Int J Med Microbiol. 2011 Apr;301(4):303-9. doi: 10.1016/j.ijmm.2010.11.004. Epub 2011 Jan 26.

PMID:
21276750

Supplemental Content

Loading ...
Support Center